Like many patients, knowing what you may pay for treatment can be a major concern. That’s why
Bristol-Myers Squibb (BMS) is committed to helping you understand your out-of-pocket (OOP)
costs and possible resources that may help make them more affordable.
The list price for EMPLICITI* is $5,027 per infusion (every 2 weeks)
when taken with lenalidomide and dexamethasone and
$9,425 per infusion (every 4 weeks) when taken with
pomalidomide and dexamethasone. Most patients will pay less.
If you have commercial insurance:
You could pay $25 per infusion with
the BMS Oncology Co-pay Assistance
Program. Learn about this program.
If you have Medicare:
You could pay $0–$1,885 per infusion if you are receiving EMPLICITI as part of your treatment
(depending on your specific Medicare benefits). The OOP cost of more than 50% of infusions is
$25 or less.
If you have Medicare Part B, you may also have a supplemental insurance plan that will pay all
or part of your EMPLICITI costs. If you have Medicare Part C, there is an OOP maximum, and
what you will pay for EMPLICITI depends on your plan’s benefit design and the level of other
healthcare expenses you have during the year. Please check with your Medicare plan
administrator for further details.
If you have Medicaid:
You could pay $0 to $20 per infusion (depending on state plan). To find out
if you qualify for
Medicaid, or to get more information about co-payments
in your state, use this link to visit the
If you do not have insurance coverage:
If you do not have medical coverage or your insurance does not cover EMPLICITI, you may pay
the list price shown above. Patients without insurance are encouraged to call
(1-844-367-5424)(1-844-367-5424) to explore potential options.
For additional information, the
BMS Access Support® program
provides resources to
patients understand their
insurance coverage and find
information on sources of
As part of the BMS Access Support program, the BMS Oncology Co-Pay Assistance Program
may help eligible commercially insured patients pay
only $25 per infusion. BMS will cover the
rest of the cost, up to $25,000 per year.
*As of January 2019. Assuming an average patient weight of 75 kg and not inclusive of cycle 1 and 2. The cost of
treatment may vary depending on patient weight.
The recommended dosage of EMPLICITI when used with Revlimid® (lenalidomide) and dexamethasone is
10 mg/kg administered intravenously every week for the first two cycles (28-day cycle) and every 2 weeks
thereafter. Treatment is continued until disease progression or unacceptable toxicity.
The recommended dosage of EMPLICITI when used with Pomalyst® (pomalidomide) and dexamethasone is
10 mg/kg administered intravenously every week for the first two cycles (28-day cycle). Starting at cycle 3
(28-day cycle), administer EMPLICITI 20 mg/kg intravenously
every 4 weeks. Treatment is continued until
disease progression or unacceptable toxicity.